Royal Peptides
Royal Peptides supplies research compounds to qualified adults for in-vitro laboratory use. Confirm both requirements to enter.
Royal Peptides is only for adults 21+ buying for laboratory research.
Leave this site
Royal Peptides products are offered exclusively for laboratory research, analytical and scientific applications. Not for human or veterinary use.
Royal Peptides supplies compounds intended for controlled laboratory research and analytical applications.
Research onlyLaboratory materialAnalytical use
Where applicable, Royal Peptides research materials are supplied in lyophilized form. Lyophilization is a freeze-drying process used to remove moisture from material under controlled conditions.
Storage requirements may vary by compound, formulation and production lot. Refer to the product label and available product-specific documentation.
Packaging components may vary slightly between production lots. This can include vial closures, cap styles, label positioning and external packaging.
Research noticeFor laboratory and research purposes only. Not intended for human consumption, diagnostic or therapeutic use, or administration to humans or animals.
Loretta™ 12.5mg is an exclusive Royal Peptides premium research blend combining Retatrutide 10mg with Eloralintide 2.5mg in a single lyophilized research formulation. The blend is designed for advanced laboratory investigation of two distinct metabolic signaling compounds within one defined research material.
Loretta™ is Royal Peptides' proprietary name for a dual-compound research formulation containing 10mg Retatrutide and 2.5mg Eloralintide, providing 12.5mg total research material per vial.
The formulation brings together two structurally and mechanistically distinct investigational compounds that have attracted substantial interest in modern metabolic research.
Retatrutide has been investigated as a GLP-1, GIP and glucagon receptor agonist, while Eloralintide is being investigated through a different signaling system involving the amylin receptor family.
Combining these compounds creates a defined laboratory material for researchers interested in studying the interaction of incretin, glucagon and amylin-associated signaling pathways within experimental models.
Each Loretta™ research vial contains a defined 4:1 ratio of Retatrutide to Eloralintide by stated mass.
Retatrutide, also identified in the scientific literature as LY3437943, is an investigational peptide engineered to interact with three metabolically relevant receptor systems: GLP-1, GIP and glucagon receptors.
This multi-receptor pharmacology has made Retatrutide an important research compound for investigating integrated metabolic signaling rather than a single isolated receptor pathway.
Experimental and clinical research has examined Retatrutide in relation to areas including energy-balance signaling, glucose-associated pathways, lipid metabolism and metabolic regulation.
Eloralintide, also known by the development identifier LY3841136, is an investigational long-acting amylin receptor agonist being studied as a distinct approach to metabolic signaling research.
Amylin is a peptide hormone associated with pancreatic beta-cell biology and participates in signaling systems involved in nutrient and energy regulation.
Eloralintide is therefore scientifically distinct from the incretin/glucagon receptor pharmacology represented by Retatrutide. This difference is central to the research rationale behind examining the compounds together in a controlled laboratory environment.
The scientific interest in a Retatrutide and Eloralintide research blend comes from the fact that the two compounds engage different receptor systems.
Retatrutide provides a research model involving GLP-1, GIP and glucagon receptor activity.
Eloralintide introduces a separate amylin-associated receptor pathway into the experimental model.
Loretta™ therefore provides researchers with a single defined formulation for investigating how these distinct signaling systems may interact in experimental settings.
Because combination-specific evidence may differ from evidence for either compound individually, findings involving Retatrutide alone or Eloralintide alone should not automatically be attributed to the Loretta™ blend.
Contemporary metabolic research increasingly examines communication among multiple receptor systems rather than treating individual pathways as completely isolated mechanisms.
Loretta™ combines compounds associated with four major areas of receptor research:
The Loretta™ formulation is intended for advanced laboratory investigation where researchers require both Retatrutide and Eloralintide within a defined research blend.
Investigation of GLP-1, GIP, glucagon and amylin-associated receptor systems.
Experimental investigation of interconnected pathways associated with metabolic regulation.
Research examining signaling mechanisms associated with energy homeostasis and nutrient-response biology.
Controlled investigation of two mechanistically distinct compounds within a single experimental formulation.
Loretta™ was developed as a distinct Royal Peptides research formulation rather than simply presenting the two compounds as unrelated research materials.
Each vial provides a clearly defined 10mg Retatrutide + 2.5mg Eloralintide composition, allowing researchers to work from a consistent 12.5mg combined formulation.
Loretta™ is an exclusive Royal Peptides research blend containing 10mg Retatrutide and 2.5mg Eloralintide, for a total stated research content of 12.5mg.
Loretta™ contains two investigational research compounds: Retatrutide 10mg and Eloralintide 2.5mg.
Retatrutide, also known as LY3437943, is an investigational peptide studied for activity involving GLP-1, GIP and glucagon receptor signaling.
Eloralintide, also known as LY3841136, is an investigational long-acting amylin receptor agonist being studied in metabolic research.
Loretta™ contains 10mg Retatrutide and 2.5mg Eloralintide, representing a 4:1 ratio by stated mass.
No. Loretta™ is a dual-compound Royal Peptides research blend. Retatrutide is one component of the formulation, with Eloralintide serving as the second component.
Loretta™ is a research blend. Research involving either individual component should not be interpreted as evidence establishing the safety or efficacy of this specific combined formulation.
No. Loretta™ is supplied strictly as research material and is not intended for human or veterinary use.
| PubChem CID | 175663130 |
|---|---|
| Application | Amylin receptor pharmacology research |
| Compound class | Investigational amylin receptor agonist |
| Also known as | LY3841136, LY-3841136 |
| Sequence / chemistry notes | Investigational amylin receptor agonist; exact modified sequence and formula not assigned without a verified chemical reference. |
| Molecular formula | C201H319N49O65S2 |
| Molecular weight | 4526 g/mol |
| CAS number | 2883634-40-8 |
| Purity specification | ≥99% |
| Form | Lyophilized powder |
| Storage | Store at −20°C |
Independent lab results for each lot. Match the lot number on your vial to its report.
View Retatrutide + Eloralinti COAs →Orders placed before the daily cut-off ship the same business day when in stock, in plain, secure packaging with tracking.
Store unopened vials frozen (−20 °C), protected from light and moisture. Follow the storage conditions on the product label and the batch COA.
| PubChem CID | 175663130 |
|---|---|
| Application | Amylin receptor pharmacology research |
| Compound class | Investigational amylin receptor agonist |
| Also known as | LY3841136, LY-3841136 |
| Sequence / chemistry notes | Investigational amylin receptor agonist; exact modified sequence and formula not assigned without a verified chemical reference. |
| Molecular formula | C201H319N49O65S2 |
| Molecular weight | 4526 g/mol |
| CAS number | 2883634-40-8 |
| Purity specification | ≥99% |
| Form | Lyophilized powder |
| Storage | Store at −20°C |
